Vanguard Capital Wealth Advisors’s GSK GSK Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$204K	Buy	+4,017	New	+$206K	0.24%	101

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Capital Wealth Advisors's GSK Position: Q2 2020 in Review

Vanguard Capital Wealth Advisors opened a new position in GSK (GSK) in Q2 2020: 4,017 shares worth $204K. The stake represents 0.24% of the portfolio and ranks #101 among its holdings.

840 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

Vanguard Capital Wealth Advisors held 4,017 shares of GSK worth $204K as of Q2 2020.
GSK was a new Vanguard Capital Wealth Advisors position in Q2 2020.
GSK made up 0.24% of Vanguard Capital Wealth Advisors's portfolio in Q2 2020, its #101 holding.
840 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q2 2020, filed 5 Aug 2020.